Ablatherm ® - HIFU for Prostate Cancer: A 10-year European Experience. A symposium sponsored by. Open Questions on the Role of HIFU as a Low Side Effects Option in the Treatment of Localized Prostate Cancer: "A medical oncologist point of view.". U. Tirelli, Aviano (IT)
Ablatherm® - HIFU for Prostate Cancer:A 10-year European Experience
A symposium sponsored by
as a Low Side Effects Option in the Treatment of Localized Prostate Cancer:
"A medical oncologist point of view."
U. Tirelli, Aviano (IT)
National Cancer Institute, Aviano
Ablatherm®- HIFU for prostate cancer : a 10-year European experience
A symposium sponsored by
Population (without PCa)
The Prostate Cancer IncidenceCompared to Other Tumors :
for Research on Cancer
(elderly pts with localized PCa) - 1 -
A study on 48.000 men with localized PCa and age between 65 and 80 years conducted in USA based on data of US SEER between 1991-99, showed that of those 34.000 men who were treated with curative approach (surgery or RT) the median survival was significantly superior to that of those 14.500 men who were treated with only watchful waiting approach (13 yrs vs. 10 yrs).
Yu-Ning Wong, Fox Chase Center, Philadelphia
Prostate Cancer Symposium, Feb. 2006
(elderly pts with localized PCa) - 2 -
The Breast Cancer Model Adapted to PCa in Early/local Disease
The quandrantectomy + RT has replaced mastectomy with obvious cosmetic /psychological advantages and identical survival
HIFU could replace RT or Radical Prostatectomy in some indications, with many benefits in terms of Quality of life and patient’s psychology and with a similar life expectancy
The Breast Cancer Model Adapted to PCa in Locally Advanced Disease
The neoadjuvant therapy (hormonal + CT) allowed a lower rate of mastectomiesand more patients treated by quadrantectomies + RT
Neoadjuvant therapy (hormonal + CT) should lead to less RT and/or Prostatectomies and more HIFU procedures
Treated by HIFU - 1 -
Treated By HIFU - 2 -
From the medical oncologist point of view, that often is the requested “referee” between surgical and radiotherapeutical option from patients with localized prostate cancer, HIFU seems a very attractive (in terms of efficacy and safety) approach for localized PCa, in particular in the elderly patients (>70 years of age).
At our cancer institution, both surgeons and radiotherapists are concordant for the introduction of HIFU in the management of our patients, both with localized and local advanced PCa.